Congenital Heart Disease and COVID-19: A Single-Center Experience

Basit Öğe Kaydı
dc.authoridGozukara Bag, Harika Gozde/0000-0003-1208-4072
dc.authoridÖncül, Mehmet/0000-0001-5874-7826
dc.authoridKarakurt, Cemsit/0000-0002-9246-8107
dc.authorwosidGozukara Bag, Harika Gozde/ABG-7588-2020
dc.authorwosidÖncül, Mehmet/ABV-4995-2022
dc.contributor.authorOncul, Mehmet
dc.contributor.authorKarakurt, Cemsit
dc.contributor.authorElkiran, Ozlem
dc.contributor.authorGozukara, Harika Gozde
dc.date.accessioned2024-08-04T20:52:13Z
dc.date.available2024-08-04T20:52:13Z
dc.date.issued2022
dc.departmentİnönü Üniversitesien_US
dc.description.abstractBackground: Coronavirus disease 2019 (COVID-19) has been infecting children since December 2019 and has caused a severe epidemic and millions of deaths worldwide. COVID-19 has severe clinical effects and is more complicated to manage in patients with underlying diseases, such as congenital heart disease (CHD), past surgical operations, arrhythmia, and end-organ damage. Objectives: This study aimed to evaluate the clinical course, follow-up, and treatment process of patients with CHD and COVID-19 in Inonu University Faculty of Medicine, Department of Pediatrics, Turkey during March 2020-February 2021. Methods: This retrospective study was performed on patients with CHD and COVID-19 in the Department of Pediatrics at Inonu University Faculty of Medicine during March 2020-February 2021, selected by making full count sampling. Admission complaints, clinical findings, biochemical parameters, echocardiography results, hospitalization times, treatments, and clinical follow-up findings were retrieved from patients' files. Results: 11 patients with underlying CHD and COVID-19 were evaluated retrospectively during the study. Ten patients were hospitalized and treated due to COVID-19. Treatment of seven of these patients continued in the intensive care unit (ICU), and five were followed up under a mechanical ventilator. Two patients died during follow-up in the ICU. Conclusions: The clinical course of COVID-19 is severe, and the mortality rate is high in patients with serious diseases, such as underlying CHD. Therefore, COVID-19 in patients with CHD requires more serious and careful follow-up.en_US
dc.identifier.doi10.5812/ijp-120978
dc.identifier.issn2008-2142
dc.identifier.issn2008-2150
dc.identifier.issue2en_US
dc.identifier.scopus2-s2.0-85134668886en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.urihttps://doi.org/10.5812/ijp-120978
dc.identifier.urihttps://hdl.handle.net/11616/100799
dc.identifier.volume32en_US
dc.identifier.wosWOS:000806564500014en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherBrieflanden_US
dc.relation.ispartofIranian Journal of Pediatricsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectChilden_US
dc.subjectCongenital Heart Diseaseen_US
dc.subjectCOVID-19en_US
dc.titleCongenital Heart Disease and COVID-19: A Single-Center Experienceen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu